Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEQUEL-Breast
NCT05392608Phase 2Active, not recruiting
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Jun 2022
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alpelisib in breast cancer, sponsored by Borstkanker Onderzoek Groep. Started Jun 2022; status: active, not recruiting.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05392608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05392608.